Novobrace Technology

Our patented technology, Novobrace, is a chemically made internal brace formed by injection of a crosslinking agent directly into the tendon or ligament, immediately adding mechanical support to the injury. This newly formed, flexible brace prevents further propagation of the lesion, provides better stronger healing, and results in the horse returning to full work significantly faster. Crosslinking therapy has also been shown to increase nutritional support to avascular tissues (like tendons); improving nutritional status facilitates the natural healing process. Novobrace may be used as a standalone therapy and also as an adjunct therapy with other tissue healing therapies including stem cells and growth factors. Unlike many other treatments commonly used by veterinarians to treat such injuries, Novobrace does not depend on a biological response or the animal’s immune system for efficacy and can dramatically reduce recovery time for the horse.

Research Supports the Use of Novobrace Technology
Over one hundred horses to date have been successfully injected with Novobrace to date. Numerous articles have been published on Novobrace technology, Nonsurgical Exogenous crosslink Therapy. In fact, the main ingredient in Novobrace is currently being investigated for the treatment of spinal disc disease in humans and has undergone extensive research in this area. Several studies have been performed testing the product on equine tendons. Both in the lab and in the field, Novobrace has shown efficacy with minimal side-effects.

Novobrace technology, Nonsurgical Exogenous crosslink Therapy, published articles include:

Chuang, S-Y et al. Effects of Exogenous Crosslinking on In Vitro Tensile and Compressive Moduli of Lumbar Intervertebral Discs , Clinical Biomechanics, 22:14-20, 2007.
Chuang, S-Y et al. The Influence of Exogenous Crosslinking and Compressive Creep Loading on Intradiscal Pressure, Biomech Model Mechanobiol. 9: 533-538, 2010.
Chuang, S-Y et al. The Effects of Exogenous Crosslinking on Hydration and Fluid Flow in the Intervertebral Disc Subjected to Compressive Creep Loading and Unloading, Spine, 35: E1362-6, 2010.
Fessel, G, et al. Exogenous Collagen Cross-Linking Recovers Tendon Functional Integrity in an Experimental Model of Partial Tear, J Orthop Res 30: 973-981, 2012.
Fessel, G, et al. Dose- and Time-Dependent Effects of Genipin Crosslinking on Cell Viability and Tissue Mechanics – Toward Clinical Application for Tendon Repair, Acta Biomaterialia, 10: 1897–1906, 2014.
Popovich, J,et al. Exogenous Collagen Crosslinking of the IVD Restores Joint Stability following Lumbar Posterior Decompression Surgery, Spine 3: 1-6, 2011.
Slusarewicz, P et al. Optimization of Protein Crosslinking Formulations for the Treatment of Degenerative Disc Disease, Spine, 36: E7-13, 2011.
Slusarewicz, P et al. Kinetic Characterization and Comparison of Various Protein Crosslinking Reagents Suitable for Tissue Engineering, J Mater Sci Mater Med., 21:1175-81, 2010.
Slusarewicz, P et al. T. Studies on the degradation of genipin in aqueous solution, Natural Products Communications, 5: 1853-8, 2010.
Zhu, K et al. Thermal Analysis Reveals Differential Effects of Various Crosslinkers on Bovine Annulus Fibrosis, J Orthop Res., 29: 8-13, 2011.

Download The Science Behind Novobrace here.